Leerink Partnrs cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a strong-buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. Several other equities research analysts have also recently commented on the company. StockNews.com raised Regeneron Pharmaceuticals from a buy rating to a strong-buy rating in a research […]

BMO Capital Markets reiterated their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) in a research report released on Tuesday morning, Benzinga reports. They currently have a $1,300.00 price objective on the biopharmaceutical company’s stock. Several other analysts have also weighed in on REGN. TD Cowen upped their price objective on Regeneron […]

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report)‘s stock had its “market perform” rating restated by Leerink Partners in a report released on Tuesday, MarketBeat.com reports. They presently have a $1,077.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $1,175.00. Leerink Partners’ target price suggests a potential upside of 4.45% […]

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report)‘s stock had its “buy” rating reissued by Truist Financial in a research report issued on Tuesday, Benzinga reports. They currently have a $1,200.00 target price on the biopharmaceutical company’s stock. Truist Financial’s price objective indicates a potential upside of 16.37% from the stock’s current price. Several other brokerages […]

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) was downgraded by equities research analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports. REGN has been the topic of several other research reports. BMO Capital Markets restated an “outperform” rating and issued a […]